Platform Advantage Eyevensys’ EyeCET platform enables non-viral, electro-transfection delivery to the eye, driving sustained local production of therapeutic proteins. This platform differentiator supports collaboration with ophthalmology clinics, biotech or pharma partners seeking safer, patient-friendly, long-term treatments and potential multi-disease applications. The approach also positions Eyevensys for co-development, licensing deals, and new funding conversations.

Orphan Focus EYS606 targets non-infectious uveitis and has orphan designation from regulatory authorities, with Phase I/II cleared to commence and a multicentre study underway in France and the UK. This creates opportunities to partner with academic medical centers and regional ophthalmology networks for trial recruitment, and to discuss regional licensing or collaboration with companies seeking NIU therapies.

Device Partnerships Eyevensys has established device-focused partnerships with Phillips-Medisize and Minnetronix to optimize design and manufacturing of ocular delivery components (ETIS). This track record enables sales discussions with additional OEMs or contract manufacturers seeking to incorporate EyeCET-based delivery into their ophthalmic portfolios and to scale production.

AMD Expansion EYS809 expands the pipeline with a DNA plasmid encoding aflibercept and decorin for wet AMD, signaling a broader addressable market in chronic retinal diseases. This presents cross-sell opportunities to retina clinics and pharma partners, and potential collaborations to pilot local protein production in AMD workflows.

Growth Readiness Eyevensys operates at a phase where strategic partnerships and co-investment can accelerate development and market entry. The company’s international trial activity and regulatory clearances support outreach to investors and corporate partners with ophthalmology portfolios to explore co-development, licensing, and manufacturing collaborations for EU, UK, and beyond.